<DOC>
	<DOCNO>NCT00000729</DOCNO>
	<brief_summary>To determine toxicity low dose foscarnet administer 4 week HIV infect patient asymptomatic , AIDS , HIV associate condition CD4+ lymphocyte count &lt; 500 cells/mm3 . To obtain preliminary efficacy data . Although zidovudine ( AZT ) effective treat AIDS patient , AZT toxic effect many patient mean treat HIV-infected person need evaluate . In vitro ( test tube ) study show human herpes virus inhibited foscarnet number retrovirus , include HIV , sensitive . It hop treatment HIV-infected individual foscarnet early phase HIV infection reduce risk develop AIDS .</brief_summary>
	<brief_title>A Multicenter Study To Determine Foscarnet Dose Response HIV Infected Patients With PGL and/or Constitutional Disease</brief_title>
	<detailed_description>Although zidovudine ( AZT ) effective treat AIDS patient , AZT toxic effect many patient mean treat HIV-infected person need evaluate . In vitro ( test tube ) study show human herpes virus inhibited foscarnet number retrovirus , include HIV , sensitive . It hop treatment HIV-infected individual foscarnet early phase HIV infection reduce risk develop AIDS . Patients divide three group : ( 1 ) asymptomatic patient without persistent generalize lymphadenopathy ( PGL ) syndrome ; ( 2 ) patient AIDS ; ( 3 ) patient mild moderate sign symptom consistent HIV infection . Patients randomly choose receive one three different foscarnet dos . The drug give 4 week , 1-hour infusion administer every 8 hour . In addition , patient clinically stable experience severe toxicity end 4 week may continue treatment , form single daily dose foscarnet administer 5 day per week . Blood sample take treatment first , fourth , eighth week treatment . If patient maintenance , blood sample take weekly . Effective 7-17-89 , patient enter study assign low foscarnet dose . Patients receive daily treatment 28 day . Patients clinically stable without severe toxicity 4 week option maintenance therapy foscarnet .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine secondary Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Short course therapy oral acyclovir ( ACV ) = &lt; 7 day . Short course therapy ketoconazole = &lt; 7 day patient respond therapy . Flurazepam . Diphenhydramine . Prior Medication : Allowed : Systemic therapy , prophylaxis maintenance AIDSdefining opportunistic infection . Patients follow finding may include : Asymptomatic HIV patient without lymphadenopathy . Patients AIDS define CDC surveillance case definition . Patients past present mild moderate sign symptom consistent HIV infection . p24 antigen serum = &gt; 60 pg/ml . Exclusion Criteria Coexisting Condition : Patients follow exclude : Ongoing systemic therapy / prophylaxis / maintenance AIDSdefining opportunistic infection . Symptomatic visceral Kaposi 's sarcoma ( KS ) , progression KS within month prior entry study , concurrent neoplasm KS basal cell carcinoma skin situ carcinoma cervix . Cytomegalovirus ( CMV ) retinitis . AIDS dementia . Concurrent Medication : Excluded : Antiretrovirals . Immunomodulatory agent . Corticosteroids Other systemic antiviral antimicrobial agent . Experimental medication . Excluded chronic basis discourage &gt; 72 hour : Acetaminophen . Narcotics . Aspirin . Concurrent Treatment : Excluded : Transfusion dependency requirement 2 unit blood per month . Patients follow exclude : Ongoing systemic therapy / prophylaxis / maintenance AIDSdefining opportunistic infection . Symptomatic visceral Kaposi 's sarcoma ( KS ) , progression KS within month prior entry study , concurrent neoplasm KS basal cell carcinoma skin situ carcinoma cervix . Cytomegalovirus ( CMV ) retinitis . AIDS dementia . Prior Medication : Excluded within 30 day study entry : Antiretroviral agent ( except ribavirin ) . Immunomodulatory agent . Excluded within 60 day study entry : Ribavirin . The last blood transfusion give within 2 week entry . Active substance abuse could impair compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Virus Replication</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>CD4-Positive T-Lymphocytes</keyword>
</DOC>